Heidelberg Pharma AG (HPHA)
XETRA Stock Exchange · Germany · prices in EUR · close of 19 Oct 2026
Key indicators
| Last close | EUR 2.200 |
|---|---|
| 52-week range | 2.150 – 3.340 |
| Return, 1 month / 3 months | −12.7% / −14.4% |
| Return, 1 year / 3 years | −25.2% / −21.7% |
| Trend | Below its 200-day average |
| RSI (14) | 35 |
| Volatility (1 year) | 36.7% |
| Worst drawdown (1 year) | -32.3% |
| Average daily value traded | 0.01M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Heidelberg Pharma is a biopharmaceutical company based in Germany that develops antibody-drug conjugates for treating cancer. Its work centres on a proprietary payload technology using amatoxins, substances derived from a poisonous mushroom, which are attached to antibodies to deliver cell-killing agents to tumour cells. The company advances its own candidate therapies through preclinical and clinical development and also provides contract research services to other drug developers.
The shares are listed on the XETRA Stock Exchange in Germany under the code HPHA, and the price on this page is in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Heidelberg Pharma AG (HPHA) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 2.200 on 19 October 2026.
Its price-based Market X-Ray is 29 out of 100 (a weak price profile), ranking 576 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 25.2% and over the last three months it fell 14.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 23 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -19.0% | ||
| From 52-week high | -32.3% | ||
| Momentum | 24 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -14.4% | ||
| 6-month return | -21.4% | ||
| 12-month return, skipping the last month | -14.3% | ||
| Risk (lower is better) | 47 · Weak | Volatile, with deep drawdowns. | |
| Volatility (1 year) | 36.7% | ||
| Worst drawdown (1 year) | -32.3% | ||
| Liquidity | 18 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.01M EUR | ||
| Zero-volume days | 1.7% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Risk (lower is better): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −3.1% |
|---|---|
| 1 month | −12.7% |
| 3 months | −14.4% |
| 6 months | −21.4% |
| 1 year | −25.2% |
| 3 years | −21.7% |
| 5 years | −62.8% |
Signals
| 50-day / 200-day average | 2.454 / 2.718 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.118 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.